J Cancer 2019; 10(6):1370-1374. doi:10.7150/jca.30014 This issue
1. Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan
2. Division of Nephrology, Department of Internal Medicine, Lin Shin Hospital, Taichung, Taiwan
3. Department of Surgical Pathology, Changhua Christian Hospital, Changhua, Taiwan
4. School of Medicine, Chung Shan Medical University, Taichung, Taiwan
5. Institute of Biochemistry, Microbiology and Immunology, Chung Shan Medical University, Taichung, Taiwan
6. Division of Urology, Department of Surgery, Taichung Veterans General Hospital, Taichung, Taiwan
7. Department of Medical Research, Chung Shan Medical University Hospital, Taichung, Taiwan
*These authors contributed equally to the work.
Urothelial cell carcinoma (UCC) is the most common primary malignancy of the urinary system and the second-most common type of renal cell carcinoma. Aurora kinase A (AURKA), a serine/threonine kinase, has a critical role in centrosome duplication, spindle assembly checkpoint, and cytokinesis. Here, we determined the correlation between UCC susceptibility and AURKA polymorphisms. We used real-time polymerase chain reaction to compare the genotype distributions and allelic frequencies of four single-nucleotide polymorphisms (SNPs) of AURKA, namely rs1047972, rs2273535, rs2064863, and rs6024836, between 431 UCC cases and 862 healthy controls. Logistic regression models demonstrated that the G allele of rs2064863, a genetic polymorphism of AURKA, exhibited a significant protective effect against UCC among the 862 nonsmokers. Moreover, patients with rs2064863 G allele exhibited a slightly lower risk of lymph node metastasis and those with rs6024836 G allele exhibited a lower risk of distant metastases. Our study suggested that several variants of AURKA SNPs rs2064863 and rs6024836 may serve as critical predictors for the clinical status of UCC.
Keywords: urothelial cell carcinoma, Aurora kinase A, susceptibility, single nucleotide polymorphism